Key Highlights

● Ginkgo traded at $12.74 by late morning.

● It will give in-kind access to its autonomous Boston lab.

● Financial terms beyond the in-kind arrangement were not reported.

● Moderna reached its highest level since 2021.

Ginkgo Bioworks (NYSE:DNA) soared on Friday, trading at $12.74 by late morning and ranking among the day's strongest biotech gainers on a movers list. Ginkgo will provide in-kind access to its autonomous laboratory in Boston for the National Science Foundation's X-Labs programme, according to market data.

In-kind access means Ginkgo will contribute use of its facilities and capabilities rather than receiving a conventional contract payment. Financial terms beyond the in-kind arrangement were not reported.

What an autonomous lab does

Ginkgo describes itself as a platform for cell programming, using biology to design organisms and molecules for uses ranging from medicines to agriculture and industrial chemicals. Its foundries combine robotics, software and large-scale data to run vast numbers of biological experiments with little manual work.

An autonomous lab takes that further, using automation and computer models to design experiments, run them and learn from the results in a loop. The idea is to speed up scientific discovery and cut costs. That pitch fits neatly with the current enthusiasm for applying artificial intelligence to research, and Ginkgo has increasingly positioned its lab services as a tool for scientists outside the company.

Two themes at once

Ginkgo also benefited from a broader rally in biotech. The move was linked to a report about a planned public-private initiative involving the National Institutes of Health to accelerate cancer vaccines, which is expected to start in December. That report sent Moderna (NASDAQ:MRNA) to its highest level since 2021 and lifted Novavax (NASDAQ:NVAX), BioNTech (NASDAQ:BNTX) and Arcturus (NASDAQ:ARCT).

Tools and genomics companies joined in. Twist Bioscience (NASDAQ:TWST), which makes synthetic DNA, and 10x Genomics (NASDAQ:TXG) climbed, and the iShares Biotechnology ETF rose sharply. Health care was among the best-performing S&P 500 sectors on the day.

Ginkgo's shares have been highly volatile over the years, and shares like these can swing sharply in both directions on news and sector sentiment.

Market backdrop

The broad market rose on Friday. The S&P 500 gained 46.18 points to 7,811.54, finishing just below its record close, while the Dow added 423.31 points to 51,654.95 and the Nasdaq Composite climbed 172.83 points to 27,366.17. On the NYSE, gainers outnumbered losers by about 1.65 to 1, but more stocks hit new lows than new highs.

Higher rates continue to weigh on companies that are not yet consistently profitable. Borrowing costs remain elevated, with the 10-year Treasury Yield near a 24-year high after the Federal Reserve's first rate increase since 2023 in September. On Thursday, Fed Governor Christopher Waller said he anticipates more rate increases to return Inflation to the Fed's goal.

Ross Mayfield, Investment strategy analyst at Baird, described the mood across markets: "It's the kind of back-and-forth market we've been in where we have the Reversal of sentiment around Iran".

How NSF X-Labs Is Structured Will Show Ginkgo's Demand Potential

Investors will look for more detail on how Ginkgo's work with the NSF X-Labs programme will be structured, and whether it leads to broader government or commercial demand for its lab services. Further clarity on the NIH cancer-vaccine initiative could keep biotech in focus. Macro catalysts include September consumer price data on Wednesday, October 14, bank Earnings from October 13 to 16 and the Fed meeting on October 27 to 28. Monday, October 12 brings a stock session but no bond trading, because of Columbus Day.